A site where you can find recommended contractors for non-clinical testing|effical " Essential Information Before Requesting a Nonclinical Study " List of Animal Models Used in Nonclinical Studies

List of Animal Models Used in Nonclinical Studies

Table of Contents
Table of Contents

Nonclinical animal studies using defined animal models are a critical step in new drug development. Different species show differing propensities to develop specific diseases, and feasibility factors—such as ease of handling and husbandry—also influence species selection. In addition, animal studies must be conducted under applicable regulations.

This overview outlines the importance of animal studies, the criteria for species selection, and the regulations and ethics that govern experimental environments and the use of live animals.

Importance of Animal Studies and Species Selection

In studies that support new drug development, appropriate use of nonclinical models and species is fundamental to generating data that can predict responses in humans. This is especially important for biologics. Consequently, science-driven strategies are used to select the most predictive test systems and species.

Species Selection Criteria

Species are selected based on similarities to humans in pharmacodynamics (PD), pharmacokinetics (PK), physiology, and pathophysiology. Rodent and non-rodent species are commonly used as disease models in which data from nonclinical studies support initial dose calculations and projections of therapeutic dose ranges for subsequent clinical development.

Feasibility is also an important consideration. Availability of animals and ease of handling in a standard laboratory environment are evaluated so that studies are conducted efficiently and ethically.

Regulations and Ethics of Animal Research

Animal research is an important means of advancing human health and welfare; at the same time, animal welfare must be respected. In Japan, strict standards for the care and use of laboratory animals have been established under the Act on Welfare and Management of Animals.

The 3Rs (Replacement, Reduction, Refinement)

When conducting animal studies, adherence to the 3Rs is required:

Researchers must carefully consider the necessity and ethical appropriateness of any animal study. Protocols are generally reviewed by an ethics committee, and study designs and procedures undergo rigorous review. This process helps ensure that scientifically useful data are obtained while maximizing consideration for animal welfare.

Reference (house style)::Japanese Association for Laboratory Animal Medicine (JALAM). https://jalam.ne.jp/mechanism/
3 Recommended Contract Research Organizations for Non-Clinical Studies
— by Target goal and Expertise

In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D. In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening. Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.

Pharmacology (Efficacy) Studies
Replicate unknown pathological models and
Discovery to clinically oriented drug evaluation
SMC Laboratories, Inc.
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/jp/)
  • SMC Laboratories, Inc. has established a disease models using patented mouse technologies. The company has established proprietary pathological models—particularly in liver disease and fibrosis—and continues to expand their approach across a wide range of models in cancer, inflammation, and metabolic diseases.
  • From exploratory research to clinically oriented efficacy evaluation, SMC offers customized study designs, dosing strategies, and evaluation analysis tailored to each project. Their collaborative approachallows researchers to discuss and refine study plans together with SMC’s expert scientists.

  • With flexible small-scale study options and strong technical support, SMC Laboratories, Inc. is an ideal partner for start-ups, biotech ventures, and academic institutions alike.
Safety Studies
Comprehensive Safety Evaluation for FIH Applications
Labcorp Holdings Inc.
(Labcorp Drug Development)
Labcorp Holdings Inc.
Reference: Labcorp Holdings Inc. official website (https://jp.labcorp.com/)
  • Labcorp Holdings Inc. provides a fully integrated GLP testing system aligned with international regulatory standards, including FDA, EMA, and PMDA requirements. All studies are conducted under ICH-compliant quality assurance, making it ready for data submission.
  • The company has extensive expertise in long-term toxicity studies such as Segment I–III reproductive and carcinogenicity studies, as well as 2-year chronic toxicity assessments.
  • Labcorp Holdings Inc.’s comprehensive approach enables sponsors to efficiently outsource the entire preclinical package from toxicology, toxicokinetic (TK), and safety pharmacology study design to execution. This accelerates a path to First-in-Human (FIH) trials. For most of the global drug developers, this all-in-one service structure minimizes cost, risk, and expedite the time before advancing to clinical phase.
Pharmacokinetic (PK/PD) Studies
High-Precision Bioanalysis for Clinically Predictive PK/PD Evaluation
PhoenixBio Co., Ltd.
PhoenixBio Co., Ltd.
Source: PhoenixBio Co., Ltd. Official Website (https://phoenixbio.co.jp/)
  • PhoenixBio Co., Ltd.offers pharmacokinetic and hepatic metabolism studies using their proprietary PXB-mouse®, a humanized-liver chimeric mouse model. This platform enables the acquisition of data with high clinical correlation in ADME, drug–to-drug interaction studies, bridging the gap between preclinical and clinical stages.
  • With advanced LC-MS/MS-based bioanalysis, PhoenixBio Co., Ltd. provides aseamless workflow from plasma concentration measurement and metabolite identification to quantitative validation.

  • The company offersan integrated evaluation analysiscovering pharmacokinetics, hepatotoxicity, and safety with flexibility to accommodate complex modalities such as oligonucleotide and middle-molecule therapeutics. For compounds where hepatic metabolism is a development bottleneck—or where quantitative, reproducible exposure data are critical—PhoenixBio Co., Ltd. delivers unmatched analytical precision and consistency.

By region
list of animal models
Expertise & Track Record
3 Recommended Contract Non-Clinical Testing Services